Identifying Patients With gBRCA Mutations

Who to test
Test based on age and family history
According to the NCCN Guidelines® for Genetic/Familial
High-Risk
Assessment: Breast & Ovarian, BRCA1/2 testing is recommended for patients with a breast cancer diagnosis who meet certain criteria, including but not limited to2:
  • Breast cancer diagnosed at ≤45 years
  • TNBC diagnosed at ≤60 years
  • A known mutation in a cancer susceptibility gene within the family
Test based on disease stage and breast cancer type
According to the NCCN Guidelines® for Breast Cancer, for patients with recurrent or Stage IV
HER2-negative
breast cancer under consideration for chemotherapy,
strongly consider germline BRCA1/2 testing during patient workup.3
View the complete guidelines at NCCN.org.
Testing for a gBRCA mutation at MBC diagnosis may help inform treatment planning4
REFERENCES
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc; 2018.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast & Ovarian V.2.2019. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  4. Moreno L, Linossi C, Esteban I, et al. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin Transl Oncol. 2016;18(10):981-987.